Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

-- Report is aimed at helping practitioners and the industry understand and prepare for the future by supporting the evolving needs of patients -- -- Built on robust market research and analysis of global social listening data, industry research, academic studies, and Allergan Aesthetics* proprietary global research into thousands of consumer attitudes1 -- -- Developed with specialist trend forecasting agency Wunderman Thompson Intelligence and validated by interviews with 13 leading aesthetics practitioners from around the world1 -- IRVINE, Calif. , June 17, 2022 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company, and a global leader in medical aesthetics treatments, today launched 'The Future of Aesthetics' global trends report via a high-profile virtual event for media and industry.

Allergan Aesthetics publishes 'The Future of Aesthetics' global trends report providing unrivalled insight into future of industry

- Third approved indication for SKYRIZI (risankizumab-rzaa) is supported by safety and efficacy data from two induction and one maintenance clinical trials evaluating SKYRIZI in moderately to severely active Crohn's disease, ADVANCE, MOTIVATE and FORTIFY 1-4 - As early as week 4 in the induction studies, clinical response and clinical remission were achieved by significantly more subjects treated with SKYRIZI versus placebo, as were co-primary endpoints of endoscopic response and clinical remission at week 12 and week 521-4 - Crohn's disease is chronic, systemic and progressive; most patients experience unpredictable symptoms that have a significant impact on daily life5-8 NORTH CHICAGO, Ill. , June 17, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved SKYRIZI® (risankizumab-rzaa) as the first and only specific interleukin-23 (IL-23) inhibitor for the treatment of adults with moderately to severely active Crohn's disease (CD).4 In two induction and one maintenance clinical trials, SKYRIZI demonstrated significant improvements in endoscopic response (defined as a decrease of greater than 50% from the baseline Simple Endoscopic Score in CD [SES-CD] or for patients with isolated ileal disease and SES-CD of 4, at least a 2-point reduction from baseline) and clinical remission (defined as a Crohn's Disease Activity Index [CDAI] of less than 150), compared to placebo, as both an induction and maintenance therapy.4 Experience the interactive Multimedia News Release here: https://www.multivu.com/players/English/8978352-abbvie-fda-crohns-disease/  "We are proud to offer the first new treatment option in six years for moderately to severely active CD, which may provide patients with a meaningful level of endoscopic improvement," said Thomas Hudson, M.D.

SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults

Bristol-Myers

Royalty Pharma

Verizon

Wells Fargo

One of Berkshire Hathaway's longest-held stocks was given the heave-ho in the first quarter.

5 Stocks Warren Buffett Has Aggressively Sold Since 2022 Began

Coca-Cola

Raytheon Technologies

With many investors focusing on the decline in the S&P 500, you might be surprised to know there are companies that are greatly outperforming the index. In some cases, certain stocks have seen a total return that is more than 20% ahead of the benchmark's return year to date.

3 Dividend-Paying Stocks Vastly Outperforming the S&P 500

Jazz Pharmaceuticals

Scotts Miracle-Gro

Top Marijuana Stocks To Watch For More Momentum In June The post 3 Marijuana Stocks That May See A Turnaround In Trading This Month appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™.

3 Marijuana Stocks That May See A Turnaround In Trading This Month

Pioneer Natural Resources

The S&P 500 index down more than 20% for the year is an opportunity to position your long-term portfolio for remarkable profits, says the Chief Investment Officer of Pivotal Advisors. Reason to stay in the market right now Tiffany McGhee quoted historical data to explain why now is an opportunistic time for the long-term investors […] The post SPX now in bear market territory: these two stocks are still a buy appeared first on Invezz.

SPX now in bear market territory: these two stocks are still a buy

ABBV stock can move higher as it trades at a very reasonable valuation. Meanwhile, AbbVie's financials and dividend payments sweeten the deal.

Consistent Clinical Results Indicate Upside for AbbVie Stock

Becton, Dickinson and Co.

Black Hills

Colgate-Palmolive

Illinois Tool Works

Leggett & Platt

Stanley Black & Decker

One thing has become painfully obvious, after Friday's consumer price index reading came in at a scorching 8.6% year over year, the highest reading since 1981.

7 ‘Strong Buy' Dividend Kings to Own Now If the Fed Rate Increase This Week Is Huge

AbbVie could report extremely high growth rates for revenue and earnings per share since 2013. While analysts are rather pessimistic, management is expecting high-single-digit growth rates after 2025.

AbbVie: Not Perfect, But Largely Recession-Proof

Novavax

Pfizer

Should investors be keeping an eye on these movers in the biotech space?

Top Biotech Stocks To Invest In Today? 3 To Watch This Week

–  Epcoritamab shows clinically meaningful efficacy in challenging-to-treat, highly refractory LBCL patients – Total patient population achieved overall response rate (ORR) of 63 percent and complete response (CR) of 39 percent; CAR T-naïve patients achieved 69 percent ORR and 42 percent CR; patients previously treated with CAR T achieved a 54 percent ORR and 34 percent CR –  Safety profile is consistent with previous findings observed – Results were reported as part of a late-breaking oral presentation selected for the Presidential Symposium at EHA NORTH CHICAGO, Ill. , June 11, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced primary results from the large B-cell lymphoma (LBCL) expansion cohort in the EPCORE™ NHL-1 phase 2 clinical trial evaluating epcoritamab (DuoBody®-CD3xCD20), an investigational subcutaneous bispecific antibody.

AbbVie Announces Late-Breaking Results from Phase 2 Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL) at the European Hematology Association (EHA) Annual Congress

Amgen

Bank of America

Comcast

Intel

Prologis

If this roiling market is making you seasick, then it's an excellent time batten down the hatches with these reliable dividend stocks. The post 7 Dividend Stocks to Buy for Your Grandkids appeared first on InvestorPlace.

7 Dividend Stocks to Buy for Your Grandkids

AbbVie has generated outstanding returns for shareholders while paying out a hefty dividend that has been growing rapidly. Much of this success was due to the wildly profitable best-selling drug Humira.

AbbVie: Highly Uncertain Future Not Yet Priced In

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. Institutions hold 71% of shares, insiders less than 1%, and dividends yield some 4% yearly. Prior price range forecasts at today's reward/risk ratios averaged +1% yearly rate of capital gains.

AbbVie Or Pfizer: Market-Maker Hedging Tells Best Near Cap Gain

Shares of AbbVie have been performing well over the last decade as the company grew both sales and EPS. AbbVie shares are not expensive at the moment and the company has significant growth opportunities.

You Should Own AbbVie In Your Dividend Growth Portfolio

Kinder Morgan

Investors looking for passive income from holding stocks should consider these dividend stocks that offer strong payouts. The post 3 Dividend Stocks to Buy Now for 20 Years of Income Growth appeared first on InvestorPlace.

3 Dividend Stocks to Buy Now for 20 Years of Income Growth

Data is supportive of early intervention in myelofibrosis to achieve improved clinical outcomes in spleen volume reduction (SVR), symptom score, bone marrow fibrosis (BMF), and anemia Results are from an exploratory analysis of navitoclax plus ruxolitinib from Cohort 3 of the Phase 2 REFINE study in JAK inhibitor naïve myelofibrosis patients NORTH CHICAGO, Ill. , June 10, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new data from Cohort 3 of its Phase 2 REFINE study of investigational navitoclax in combination with ruxolitinib in JAK inhibitor naïve patients with myelofibrosis (MF), a rare and difficult to treat blood cancer.

AbbVie Presents Investigational Navitoclax Preliminary Data in JAK Inhibitor Naïve Myelofibrosis Patients

Five-year follow-up analysis of the Phase 3 CLL14 trial (median follow-up of 65.4 months) continues to demonstrate longer progression-free survival (PFS) after fixed-duration venetoclax plus obinutuzumab compared to fixed-duration chlorambucil plus obinutuzumab in previously untreated patients with chronic lymphocytic leukemia and coexisting conditions PFS was significantly superior for venetoclax plus obinutuzumab compared to chlorambucil plus obinutuzumab (median not reached [NR] vs. 36.4 months, p6 or creatinine clearance

New Data Demonstrates AbbVie's VENCLYXTO®/VENCLEXTA® Combination Sustained Progression-Free Survival in Chronic Lymphocytic Leukemia Patients After Four Years Off Treatment

It probably wasn't a very good fit for his investing preferences in the first place.

Warren Buffett Just Sold This Popular Stock -- Should You?

AbbVie recently shared encouraging clinical trial results for patients taking Rinvoq to treat Crohn's disease.

Here's What This Drug News Could Mean for AbbVie's Shareholders

Researchers to highlight positive results from the Phase 3 PROGRESS trial investigating atogepant (QULIPTA™) for the preventive treatment of chronic migraine Breadth of research underscores AbbVie's leadership and commitment to people living with migraine and their individual needs NORTH CHICAGO, Ill. , June 7, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it will present data from its migraine portfolio at the 2022 American Headache Society (AHS) Annual Scientific Meeting to be held in Denver, June 9-12.

AbbVie to Present Extensive Data from its Migraine Portfolio at the 2022 American Headache Society® (AHS) Annual Scientific Meeting

NEW YORK , June 7, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of AbbVie Inc. (NYSE: ABBV) alleging that the Company violated federal securities laws. Class Period: April 30, 2021 to August 31, 2021 Lead Plaintiff Deadline: June 6, 2022 No obligation or cost to you.

ABBV ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 6, 2022 in the Class Action Filed on Behalf of AbbVie Inc. Shareholders

Bigger is not always better, but it does not hurt.

If Bigger Is Better, AbbVie Stock Will Continue to Climb

Atmos Energy

Cardinal Health

Essex Property Trust

Kimberly-Clark

McDonald's

Exxon Mobil

In the history of the United States, there have been a handful of true visionaries that changed life and the world as we know it.

9 ‘Strong Buy' Dividend Aristocrats to Buy Now in Case Elon Musk Is Right

Los Angeles, California--(Newsfile Corp. - June 6, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AbbVie Inc. ("AbbVie" or "the Company") (NYSE: ABBV) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between April 30, 2021 and August 31, 2021, inclusive (the...

News for AbbVie Stock (ABBV)